PSMA
39 programs · 38 companies
Programs
39
Companies
38
Active Trials
29
Targeting PSMA
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| AZN-3724 | AstraZeneca | Preclinical | PSP | |
| Doxacagene | Sanofi | Approved | DLBCLGA | |
| GSK-2051 | GSK | Phase 1 | Heart FailureDLBCL | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PsATTR Amyloidosis | |
| BII-1564 | Biogen | Phase 2 | CeliacDLBCL | |
| BGN-3859 | BeiGene | Approved | ALSMyelofibrosis | |
| DAW-8159 | Day One Bio | Phase 2 | Dravet | |
| AGI-4446 | Agios | Phase 3 | LGS | |
| Mirimavacamten | 10x Genomics | Phase 1 | Myelofibrosis | |
| Riboderotide | CSL Limited | Phase 2 | ASPompe | |
| CSL-652 | CSL Limited | Preclinical | CTCL | |
| Rilulucimab | Otsuka | Phase 2 | LGS | |
| 460-4909 | Sihuan Pharma | Preclinical | PAHGA | |
| Bemacapivasertib | Imugene | NDA/BLA | ACCRCC | |
| NIA-IIT-954 | NIAID | Phase 2 | Thymoma | |
| SAM-IIT-936 | Samsung Medical Ctr | Phase 3 | NSCLC | |
| GIM-IIT-628 | GIMEMA | Phase 2/3 | Ewing Sarcoma | |
| Suraosocimab | Horizon (Amgen) | Phase 1 | FSGSNB | |
| Zorinaritide | Athenex | NDA/BLA | Wet AMDPancreatic Ca | |
| Zorilucimab | Imago (Merck) | NDA/BLA | TTR AmyloidosisCF | |
| DER-2537 | Dermira (Lilly) | Phase 2/3 | IgAN | |
| 302-9165 | SK Bioscience | Approved | LGSPompe | |
| GH-3607 | Guardant Health | NDA/BLA | HCC | |
| SOR-1685 | Sorrento Ther | Phase 2 | Prostate Ca | |
| HOM-3477 | Homology Med | Approved | MCLEoE | |
| Talafotisoran | Oncorus (sold) | NDA/BLA | MigraineOvarian Ca | |
| 095-5475 | Genexine | Preclinical | RCCCervical Ca | |
| BIO-4284 | Biocon | Phase 2/3 | SCDLN | |
| LPC-4508 | Lupin | Phase 1 | ThymomaGA | |
| Rimarapivir | Sinovac | Phase 3 | IPFGA | |
| IMV-2493 | Immunovant | Phase 2 | SchizophreniaGBM | |
| PCI-4776 | PCI Biotech | Phase 3 | HNSCCRett | |
| BPT-5103 | Biophytis | Phase 2 | NarcolepsyRett | |
| Zorilucimab | BioVersys | Approved | WMCLL | |
| Capiderotide | Mankind Pharma | NDA/BLA | MMAML | |
| PRO-6778 | Probiomed | Preclinical | ACC | |
| DPH-7069 | Duopharma | Phase 1 | NMOSDMyelofibrosis | |
| Sovazumab | Repligen | Phase 1 | NarcolepsySchizophrenia | |
| Tixasotorasib | Bio-Techne | Preclinical | MigraineLGS |